Portal vein thrombosis
Also known as: Vein, Venous, Clot, Thrombosed
Methodology & AI Transparency ⓘ
Portal vein thrombosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Portal vein thrombosis (also termed Vein or Venous) (I81) in Blood Pressure relies on vascular stiffness assessment [Portal vein thrombosis I81], guiding step-wise therapeutic adjustments toward Home Seated Blood in Portal vein thrombosis (I81: Pressure) (< 120/75 mmHg (I81)).
- 2 Real-world patient consensus: Clinical coding for Portal vein thrombosis uses ICD-10 I81 across Blood Pressure specialty care.
- 3 Typical cash cost range: Workup highlights for Portal vein thrombosis (I81): vascular stiffness assessment [Portal vein thrombosis I81].
- 4 Top reported side effects / signs: Objective lab/clinical target for Portal vein thrombosis: Urine Albumin-to-Creatinine Ratio [Portal vein thrombosis I81] (< 15 mg/g (I81)) and Home Seated Blood in Portal vein thrombosis (I81: Pressure).
Ask our AI Specialists anything about Portal vein thrombosis
What Is Portal vein thrombosis?
Clinical triage of Portal vein thrombosis (also termed Vein or Venous) (I81) in Blood Pressure relies on vascular stiffness assessment [Portal vein thrombosis I81], guiding step-wise therapeutic adjustments toward Home Seated Blood in Portal vein thrombosis (I81: Pressure) (< 120/75 mmHg (I81)).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in blood pressure, Portal vein thrombosis (I81) involves intimal-medial vascular remodeling [Portal vein thrombosis I81]. progression correlates with shifts in Urine Albumin-to-Creatinine Ratio [Portal vein thrombosis I81] (< 15 mg/g (I81)).
Common Symptoms & Clinical Signs
- • Presentation of Portal vein thrombosis (I81): cold distal extremities in Portal vein thrombosis (I81: or diminished peripheral)
- • Secondary Portal vein thrombosis clinical sign: persistently elevated home in Portal vein thrombosis (I81: or clinic blood)
- • Symptom flares in Portal vein thrombosis correlating with Urine Albumin-to-Creatinine Ratio [Portal vein thrombosis I81] deviation outside < 15 mg/g (I81)
- • Functional blood pressure impact requiring vascular stiffness assessment [Portal vein thrombosis I81] evaluation (I81)
Portal vein thrombosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Portal vein thrombosis I81] | < 15 mg/g (I81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Portal vein thrombosis (I81: Pressure) | < 120/75 mmHg (I81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Portal vein thrombosis I81] | 1.00 – 1.30 (I81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Portal vein thrombosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Argatroban Argatroban Generic • RxCUI 1804737 | Anti-coagulant | 80% | $3.2100 | $ 138.50 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Portal vein thrombosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of amlodipine on ambulatory blood pressure in hypertensive Patients receiving amlodipine had significantly lower blood pressure compared with placebo 24 hours after the last dose (supine blood pressure -25.1/-10.1 mm Hg; standing blood pressure -21.2/-9.7 mm Hg) after 4 weeks of... The American journal of cardiology • 1994-01-27 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 8310975 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of a novel low-dose triple single-pill combination of A novel low-dose SPC product of telmisartan, amlodipine, and indapamide provided clinically meaningful improvements in blood pressure reduction compared with dual combinations and was well tolerated. Lancet (London, England) • 2024-10-19 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 39426836 ↗ |
| New Insights on Benefits and safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related: What a 308-Participant Study Found QL1205 was biosimilar to reference ranibizumab regarding clinical efficacy, ocular and systemic safety, as well as immunogenicity and how the body absorbs the medicine profiles in the treatment of patients with nAMD. Ophthalmology. Retina • 2025-04-15 • Phase III Randomized Trial | N = 308 | 87/100 | PMID 39389463 ↗ |
| New Insights on ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in: What a 522-Participant Study Found Compared with telmisartan, enalapril was associated with a higher incidence of cough (8.9% versus 0.8%) and hypotension (3.9% versus 1.1%). The Journal of international medical research • 2002-01-15 • Randomized Controlled Trial | N = 522 | 87/100 | PMID 12526280 ↗ |
| Can This Approach Help? Inside the Latest Research on Heart and blood vessel Outcomes in high blood pressure-Treated Patients With Our results indicate that more intensive BP control is associated with a reduction in heart and blood vessel morbidity and mortality in patients with hypertensive PAD. Hypertension (Dallas, Tex. : 1979) • 2024-07-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 38716657 ↗ |
Portal vein thrombosis Patient Community & “People Like Me” Threads
Filter Portal vein thrombosis community threads and patient logs by age, biological sex, dosage, and treatment duration.